Baird reiterates Outperform rating on Owens & Minor stock, sees potential catalysts

Baird reiterated an Outperform rating and $10 price target on Owens & Minor (OMI), citing potential catalysts such as significant cash tax advantages and a possible accretive sale of its PHS division, while dismissing concerns over a suspected Kaiser contract loss. This positive outlook persists despite OMI's 52% YTD stock decline, recent Q1 2025 financials showing a revenue miss ($2.63B vs $2.66B forecast) but an EPS beat ($0.23 vs $0.20), and the costly termination of its Rotech Healthcare acquisition ($80M fee, $1B note redemption). Baird emphasizes OMI's "historic low" valuation offers substantial upside, with management focused on core Patient Direct growth and deleveraging.

Analysis

Baird has reiterated its Outperform rating and $10.00 price target for Owens & Minor (OMI), framing the stock as a compelling turnaround opportunity despite significant headwinds. This positive outlook is anchored in several potential catalysts, including cash tax advantages from the OBBBA legislation, the potential for an accretive sale of its Patient Health Solutions (PHS) division, and continued strength in the core Patient Direct business. Baird's analysis suggests investor concerns regarding a potential Kaiser contract loss may be inflated. This bullish thesis is presented against a stark backdrop: OMI's stock has declined 52% year-to-date, trading at what the firm describes as "historic lows." Recent corporate events present a mixed picture. The company surpassed Q1 2025 EPS estimates with $0.23 versus a $0.20 forecast, but missed on revenue, reporting $2.63 billion against a $2.66 billion expectation. More significantly, OMI terminated its planned acquisition of Rotech Healthcare due to regulatory challenges, incurring an $80 million termination fee and necessitating the redemption of $1 billion in notes. In response, management is focusing its strategy on organic growth in the Patient Direct segment and using cash flow for deleveraging, a plan that received strong shareholder endorsement at its recent annual meeting.

Key Decisions for Investors

• Investors with a higher risk appetite may consider the stock a deep-value play, banking on the significant upside potential if Baird's identified catalysts materialize against the current historically low valuation.
• It is crucial to monitor the company's execution on its deleveraging and organic growth strategy, particularly cash flow generation, as this is now the central pillar of the investment thesis following the costly failed acquisition of Rotech Healthcare.
• While Baird dismisses concerns, the status of the Kaiser contract remains a key variable, and any definitive news could serve as a significant positive or negative catalyst for the stock.
• The slight revenue miss in Q1 suggests that investors should closely watch top-line performance in subsequent quarters to validate the strength of the core Patient Direct business.